These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20368797)

  • 1. S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function.
    Völkers M; Rohde D; Goodman C; Most P
    J Biomed Biotechnol; 2010; 2010():178614. PubMed ID: 20368797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy.
    Kraus C; Rohde D; Weidenhammer C; Qiu G; Pleger ST; Voelkers M; Boerries M; Remppis A; Katus HA; Most P
    J Mol Cell Cardiol; 2009 Oct; 47(4):445-55. PubMed ID: 19538970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100A1: a regulator of myocardial contractility.
    Most P; Bernotat J; Ehlermann P; Pleger ST; Reppel M; Börries M; Niroomand F; Pieske B; Janssen PM; Eschenhagen T; Karczewski P; Smith GL; Koch WJ; Katus HA; Remppis A
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13889-94. PubMed ID: 11717446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance.
    Most P; Remppis A; Pleger ST; Katus HA; Koch WJ
    Am J Physiol Regul Integr Comp Physiol; 2007 Aug; 293(2):R568-77. PubMed ID: 17459908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A1: a multifaceted therapeutic target in cardiovascular disease.
    Rohde D; Ritterhoff J; Voelkers M; Katus HA; Parker TG; Most P
    J Cardiovasc Transl Res; 2010 Oct; 3(5):525-37. PubMed ID: 20645037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model.
    Pleger ST; Shan C; Ksienzyk J; Bekeredjian R; Boekstegers P; Hinkel R; Schinkel S; Leuchs B; Ludwig J; Qiu G; Weber C; Raake P; Koch WJ; Katus HA; Müller OJ; Most P
    Sci Transl Med; 2011 Jul; 3(92):92ra64. PubMed ID: 21775667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance.
    Most P; Remppis A; Pleger ST; Löffler E; Ehlermann P; Bernotat J; Kleuss C; Heierhorst J; Ruiz P; Witt H; Karczewski P; Mao L; Rockman HA; Duncan SJ; Katus HA; Koch WJ
    J Biol Chem; 2003 Sep; 278(36):33809-17. PubMed ID: 12777394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calmodulin and S100A1 fine tune skeletal muscle E-C coupling. Focus on "Modulation of sarcoplasmic reticulum Ca2+ release in skeletal muscle expressing ryanodine receptor impaired in regulation by calmodulin and S100A1".
    Bers DM
    Am J Physiol Cell Physiol; 2011 May; 300(5):C974-5. PubMed ID: 21346150
    [No Abstract]   [Full Text] [Related]  

  • 9. The C terminus (amino acids 75-94) and the linker region (amino acids 42-54) of the Ca2+-binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibers.
    Most P; Remppis A; Weber C; Bernotat J; Ehlermann P; Pleger ST; Kirsch W; Weber M; Uttenweiler D; Smith GL; Katus HA; Fink RH
    J Biol Chem; 2003 Jul; 278(29):26356-64. PubMed ID: 12721284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A1 binds to the calmodulin-binding site of ryanodine receptor and modulates skeletal muscle excitation-contraction coupling.
    Prosser BL; Wright NT; Hernãndez-Ochoa EO; Varney KM; Liu Y; Olojo RO; Zimmer DB; Weber DJ; Schneider MF
    J Biol Chem; 2008 Feb; 283(8):5046-57. PubMed ID: 18089560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes.
    Remppis A; Most P; Löffler E; Ehlermann P; Bernotat J; Pleger S; Börries M; Reppel M; Fischer J; Koch WJ; Smith G; Katus HA
    Basic Res Cardiol; 2002; 97 Suppl 1():I56-62. PubMed ID: 12479236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes.
    Most P; Boerries M; Eicher C; Schweda C; Völkers M; Wedel T; Söllner S; Katus HA; Remppis A; Aebi U; Koch WJ; Schoenenberger CA
    J Cell Sci; 2005 Jan; 118(Pt 2):421-31. PubMed ID: 15654019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100A1: a pluripotent regulator of cardiac and vascular function.
    Desjardins JF; Teichert-Kuliszewska K; Parker T
    Can J Cardiol; 2010 Mar; 26 Suppl A():9A-12A. PubMed ID: 20386753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.
    Ritterhoff J; Völkers M; Seitz A; Spaich K; Gao E; Peppel K; Pleger ST; Zimmermann WH; Friedrich O; Fink RHA; Koch WJ; Katus HA; Most P
    Mol Ther; 2015 Aug; 23(8):1320-1330. PubMed ID: 26005840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100A1: a major player in cardiovascular performance.
    Duarte-Costa S; Castro-Ferreira R; Neves JS; Leite-Moreira AF
    Physiol Res; 2014; 63(6):669-81. PubMed ID: 25157660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into the regulation of RyR1 by S100A1.
    Weninger G; Miotto MC; Tchagou C; Reiken S; Dridi H; Brandenburg S; Riedemann GC; Yuan Q; Liu Y; Chang A; Wronska A; Lehnart SE; Marks AR
    Proc Natl Acad Sci U S A; 2024 Jul; 121(27):e2400497121. PubMed ID: 38917010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction.
    Most P; Seifert H; Gao E; Funakoshi H; Völkers M; Heierhorst J; Remppis A; Pleger ST; DeGeorge BR; Eckhart AD; Feldman AM; Koch WJ
    Circulation; 2006 Sep; 114(12):1258-68. PubMed ID: 16952982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes.
    Brinks H; Rohde D; Voelkers M; Qiu G; Pleger ST; Herzog N; Rabinowitz J; Ruhparwar A; Silvestry S; Lerchenmüller C; Mather PJ; Eckhart AD; Katus HA; Carrel T; Koch WJ; Most P
    J Am Coll Cardiol; 2011 Aug; 58(9):966-73. PubMed ID: 21851887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial S100A1 modulates vascular function via nitric oxide.
    Pleger ST; Harris DM; Shan C; Vinge LE; Chuprun JK; Berzins B; Pleger W; Druckman C; Völkers M; Heierhorst J; Øie E; Remppis A; Katus HA; Scalia R; Eckhart AD; Koch WJ; Most P
    Circ Res; 2008 Apr; 102(7):786-94. PubMed ID: 18292599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting S100A1 in heart failure.
    Ritterhoff J; Most P
    Gene Ther; 2012 Jun; 19(6):613-21. PubMed ID: 22336719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.